Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
about
Treatment of dementia in Parkinson's diseaseManaging anxiety associated with neurodegenerative disordersHypothalamic-pituitary-gonadal axis involvement in learning and memory and Alzheimer's disease: more than "just" estrogenAssessment and management of behavioral and psychological symptoms of dementiaRapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil.Familiar music as an enhancer of self-consciousness in patients with Alzheimer's disease.Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care PhysicianCost-effectiveness of drug therapies for Alzheimer's disease: A brief review.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trialThe pharmacotherapy of neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in BerlinNon-pharmacological, multicomponent group therapy in patients with degenerative dementia: a 12-month randomizied, controlled trial.The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalitiesEfficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Approach to managing behavioural disturbances in dementia.Prescribing patterns for Alzheimer disease: survey of Canadian family physicians.An evaluation of primary care led dementia diagnostic services in Bristol.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsAbhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial.Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.Sufficiently important difference for common cold: severity reduction.A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.Integrating care for older adults with cognitive impairmentChemical composition, antioxidant and anticholinesterase potentials of essential oil of Rumex hastatus D. Don collected from the North West of PakistanPF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.Aggression in persons with dementia: use of nursing theory to guide clinical practice.Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.
P2860
Q24246868-103732FD-4D57-4D8C-8330-04FD34CE6FCBQ27024451-C30DE2B0-6388-4CC8-AA46-78444F5ACD04Q27027598-1FE9AF46-C941-469A-B317-B11EA38EF651Q28088782-0F429B34-5227-4D56-8A01-C570B94C423BQ28315288-4F73CDFC-7AA2-4DCB-8021-C1645AA76FFAQ30354255-4F7BBD3A-CA25-4341-A879-7A12801F57C7Q30433785-35D544C9-01F4-4A86-B262-935DA356DAC2Q30441091-9C5579E8-5334-4FEE-B391-CA500DBD395CQ30443975-473B4011-4C16-4BC1-BCC3-66A6FE8B2812Q33165693-F10FD3AE-CF11-40D0-B4BD-E8939D65CE0DQ33362745-92BBC3CA-41A3-4E0F-B17E-35EA9751CA89Q33591977-5A7A29FA-1904-4365-95DF-AC213CEA9675Q33694502-5E6B2A9F-AAC2-4F10-880F-2D860FD1417BQ33726385-AE565B1F-C134-408A-A619-EE0F9E16808BQ33736233-D049FCD2-EC62-4029-9095-B9D0EB0E5CFFQ33880702-75248052-A83A-4BA3-8BD3-E40D02D688EFQ33887166-3C828363-93D0-4FD2-BC8D-563FAD72FFA3Q34088582-F9AD7180-B6F4-48D0-BB3A-2C7545F69E48Q34343927-3854B83D-5ACC-43DC-8819-60DB19FB9833Q34409349-4AC5F629-33A7-4F47-8287-9CFEF947FAD1Q34552380-9A58AEC9-A8E4-4770-8BDB-DEA8A586B38BQ34648742-48463200-BB21-44BC-9FC7-C5C32AF30402Q34683770-04B2C7A9-4E9A-4634-9587-272786684210Q34683821-4DA84C52-4B3F-4BA9-BABC-5D9F30B21463Q34686573-6257A27D-5800-4F3A-92FC-88B22763F244Q34965949-F5FA1E3B-9EB5-4268-92C2-0FD6E75D5EBDQ35107027-6E3EECAC-F12C-452B-8797-D7B57040C0E0Q35235768-463994A4-2FAB-4C58-B051-5AC57B293EF0Q35276747-CEF07CF0-50F1-4418-8E00-1206DF9A9E42Q35748293-408408C1-7E40-49A7-9FEA-9BBC4DD28977Q35831614-58C74A38-1E6E-441A-AD80-9AFBE0D9B370Q35844609-8E0C0CFA-038B-4B3E-9AEB-53327D0163EBQ35870021-B5B866C0-194F-440B-9B01-7F4365F69B4FQ35904349-2B9B0BC2-4FA7-4331-AB2D-2723F3E7DDA5Q35940134-C314B4E5-0108-4BA2-ACDC-79E4E6B42916Q35940409-B898157C-6DE4-4021-9E78-E08815CC3B8BQ36003456-F2BFC040-9B34-448F-B8D1-FCDDE3BF7C93Q36006524-B599245D-A77E-49F8-9E79-F9B718ECE273Q36283014-0CD72350-93D8-47C9-B74F-6E67936717B5Q36310524-AF5A79AF-C899-4538-B82E-8B765BCBC8C9
P2860
Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@ast
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@en
type
label
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@ast
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@en
prefLabel
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@ast
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@en
P2093
P356
P1476
Efficacy of cholinesterase inh ...... imer disease: a meta-analysis.
@en
P2093
Jennifer Hoblyn
Nhi-Ha Trinh
Subhanjoy Mohanty
P304
P356
10.1001/JAMA.289.2.210
P407
P577
2003-01-01T00:00:00Z